Scientific Advisory Board

SmartCella has a Scientific Advisory Board (SAB), chaired by Professor Anna Martling, who also serves on the Board of Directors of SmartCella Holding AB. The SAB’s purpose is to provide scientific and clinical insights into SmartCella’s strategic direction and research programs while also anticipating future developments from both scientific and clinical perspectives.

SmartCella’s SAB brings together leading scientists, researchers, and medical specialists to discuss key topics, including innovation, efficiency, healthcare economics, sustainability, and, most importantly, improved patient outcomes across the entire healthcare system. These discussions are global in scope, grounded in scientific and clinical aspects, and take a critical, analytical approach to evaluating innovative technologies and therapies and their potential in the future of health and healthcare. At the core of the SAB’s agenda is always the well-being of patients, closely aligning with SmartCella’s overarching mission – to develop cures and transform the lives of patients in need.

The SAB consists of a core group of members with global scientific profiles and invites additional specialists based on specific thematic medical issues addressed in the agenda. The inaugural SAB roundtable, held in March 2025, focused on the need for efficient and safe delivery solutions for advanced therapies within regeneration, immunomodulation and oncology highlighting the Extroducer’s role as an innovative delivery platform.

Looking ahead, the SAB will explore other therapeutic areas, applications, and indications – delving deeper into which organs and conditions could benefit from the Extroducer’s use, as well as areas for advancing therapy development.

Members